About Event
The Ultimate Industry Forum for GLP-1 Therapeutics
The 2nd GLP-1-Based Therapeutics Summit is an exclusive gateway to competitive intelligence into the continued potential of cutting-edge GLP-1s for obesity, weight loss, diabetes, and beyond. Join us to hear the latest clinical data on combination therapies to enhance muscle preservation, indication expansion into new areas, and strategies to improve the efficacy, tolerability, and durability of GLP-1s. With these drugs continuing to dominate the headlines, there is no better time to unite with 100+ C-level executives, decision-makers, and scientists at the forefront of the rapidly evolving world of GLP-1-Based therapeutics.
What's New For 2025:
Panel and Q&A with Search & Evaluation, Partnerships & Investment executives in the GLP-1 space to dive into the scientific and commercial factors of setting up a successful partnership to develop GLP-1-based therapeutics for indications in obesity and beyond and ask your burning questions on key milestones and where the field is headed next with Novo Nordisk and Fractyl Health
The Workshop Day explores advancements in the understanding of GLP-1 mechanisms for the discovery & development of combination therapies to allow for enhanced therapeutic design and GLP-1s with increased efficacy and durability with i20 Therapeutics and the University of Palm
Join Your Peers To:
Navigate the expansion of your GLP-1s pipeline into novel areas, including MASH, age-related diseases, and neurology with Eli Lilly, Regeneron, and Neural
Explore the enhancement of GLP-1 efficacy and tolerability through a combination of analogues for improved patient experience with Roche and i20 Therapeutics
Delve into innovative clinical trial designs used in GLP-1 trials to help overcome the lack of placebo populations as the number of GLP-1 patients increases to ensure trial validity with Eli Lilly & Co and Altimmune
Discuss how novel formulations such as oral and gene therapy-based GLP-1s will affect future patient adherence and aid in the development of digital health interventions with the National Academy of Sports Medicine, Fractyl Health, and Novo Nordisk
Understand where big pharma is looking to partner in the brand new panel discussion & Q&A tackling all things search and evaluation, partnerships, and investment in the GLP-1 field with Novo Nordisk and Altimmune
Download the Full Event Guide for more information on:
- 18+ Biotech & Pharma Speakers
- 2 Interactive Workshops
- 4+ Hours of Networking
- & Much More
Who Will You Meet?
100+ senior decision makers from C-Level to senior scientists from leading GLP-1 focussed biopharma operating across obesity, weight loss, diabetes, and beyond will unite in Boston. Across preclinical, clinical, and medical development, and search & evaluation, end-to-end colleagues will unite in one room to advance specialized, durable, and efficacious GLP-1 agonists and investigate the commercial opportunity in pipeline and indication expansion.
